Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 9, Issue 1, 2006, Pages 13-33

  Lester Coll, Nataniel ^a   Rivera, Enrique J ^a   Soscia, Stephanie J ^a   Doiron, Kathryn ^a   Wands, Jack R ^a   De La Monte, Suzanne M ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Diabetes; Glycogen synthase kinase; Growth factor receptors; Insulin; RT PCR; Streptozotocin

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CHOLINE ACETYLTRANSFERASE; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; LIGAND; PHOSPHOPROTEIN; PROTEIN P53; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C RECEPTOR; SOMATOMEDIN RECEPTOR; TAU PROTEIN; UBIQUITIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SIZE; CELL LOSS; CONTROLLED STUDY; DIABETES MELLITUS; GENE EXPRESSION; GLIOSIS; NERVE CELL; NERVE DEGENERATION; NONHUMAN; OLIGODENDROGLIA; OXIDATIVE STRESS; PHASIC INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES;

EID: 33645960672     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2006-9102     Document Type: Article

References (95)

1. S.M. de la Monte and J.R. Wands, Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease, J Alzheimers Dis 7(1) (2005), 45-61.
2. E. Rivera, A. Goldin, N. Fulmer, R. Tavares, J.R. Wands and S.M. de la Monte, Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: Link to brain reductions in acetylcholine, J Alzheimers Dis 8 (2005), 247-268.
3. E. Steen, B.M. Terry, E.J. Rivera, J.L. Cannon, T.R. Neely, R. Tavares et al., Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 7(1) (2005), 63-80.
4. S. Hoyer, Glucose metabolism and insulin receptor signal transduction in Alzheimer disease, Eur J Pharmacol 490(1-3) (2004), 115-125.
5. S. Hoyer, Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications, Adv Exp Med Biol 541 (2004), 135-152.
6. S. Craft, S. Asthana, D.G. Cook, L.D. Baker, M. Cherrier, K. Purganan et al., Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype, Psychoneuroendocrinology 28(6) (2003), 809-822.
7. S. Craft, S. Asthana, G. Schellenberg, L. Baker, M. Cherrier, A.A. Boyt et al., Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype, Ann N Y Acad Sci 903 (2000), 222-228.
8. C. Messier, Diabetes, Alzheimer's disease and apolipoprotein genotype, Exp Gerontol 38(9) (2003), 941-946.
9. S. Hoyer, The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update, J Neural Transm 109(3) (2002), 341-360.
10. J.R. McDermott and A.M. Gibson, Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme, Neurochem Res 22(1) (1997), 49-56.
11. W.Q. Qiu, D.M. Walsh, Z. Ye, K. Vekrellis, J. Zhang, M.B. Podlisny et al., Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation, J Biol Chem 273(49) (1998), 32730-32738.
12. W. Farris, S. Mansourian, M.A. Leissring, E.A. Eckman, L. Bertram, C.B. Eckman et al., Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein, Am J Pathol 164(4) (2004), 1425-1434.
13. M. Schubert, D.P. Brazil, D.J. Burks, J.A. Kushner, J. Ye, C.L. Flint et al., Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation, J Neurosci 23(18) (2003), 7084-7092.
14. M. Schubert, D. Gautam, D. Surjo, K. Ueki, S. Baudler, D. Schubert et al., Role for neuronal insulin resistance in neurodegenerative diseases, Proc Natl Acad Sci USA 101(9) (2004), 3100-3105.
15. S.M. de la Monte and J.R. Wands, Alzheimer-associated neuronal thread protein mediated cell death is linked to impaired insulin signaling, J Alzheimers Dis 6(3) (2004), 231-242.
16. J. Xu, J. Eun Yeon, H. Chang, G. Tison, G. Jun Chen, J.R. Wands et al., Ethanol impairs insulin-stimulated neuronal survival in the developing brain: Role of PTEN phosphatase, J Biol Chem (2003).
17. S.M. de la Monte, T.R. Neely, J. Cannon and J.R. Wands, Ethanol impairs insulin-stimulated mitochondrial function in cerebellar granule neurons, Cell Mol Life Sci 58(12-13) (2001), 1950-1960.
18. S.M. de la Monte and J.R. Wands, Chronic gestational exposure to ethanol impairs insulin-stimulated survival and mitochondrial function in cerebellar neurons, CMLS, Cell Mol Life Sci 59 (2002), 882-893.
19. S.M. de la Monte, N. Ganju, K. Banerjee, N.V. Brown, T. Luong and J.R. Wands, Partial rescue of ethanol-induced neuronal apoptosis by growth factor activation of phosphoinositol-3-kinase, Alcohol Clin Exp Res 24(5) (2000), 716-726.
20. K. Plaschke and S. Hoyer, Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus, Int J Dev Neurosci 11(4) (1993), 477-483.
21. R. Duelli, H. Schrock, W. Kuschinsky and S. Hoyer, Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats, Int J Dev Neurosci 12(8) (1994), 737-743.
22. S. Hoyer, D. Muller and K. Plaschke, Desensitization of brain insulin receptor. Effect on glucose/energy and related metabolism, J Neural Transm Suppl 44 (1994), 259-268.
23. H. Lannert and S. Hoyer, Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats, Behav Neurosci 112(5) (1998), 1199-1208.
24. S. Hoyer, S.K. Lee, T. Loffler and R. Schliebs, Inhibition of the neuronal insulin receptor. An in vivo model for sporadic Alzheimer disease? Ann N Y Acad Sci 920 (2000), 256-258.
25. S. Hoyer and H. Lannert, Inhibition of the neuronal insulin receptor causes Alzheimer-like disturbances in oxidative/energy brain metabolism and in behavior in adult rats, Ann N Y Acad Sci 893 (1999), 301-303.
26. S.M. de la Monte, X.J. Xu and J.R. Wands. Ethanol inhibits insulin expression and actions in the developing brain, Cell Mol Life Sci 62(10) (2005), 1131-1145.
27. G. Andican and G. Burcak. Oxidative damage to nuclear DNA in streptozotocin-diabetic rat liver, Clin Exp Pharmacol Physiol 32(8) (2005), 663-666.
28. S.Y. Saad and T.A. Najjar, Effects of STZ-induced diabetes and its treatment with vanadyl sulphate on cyclosporine A-induced nephrotoxicity in rats, Arch Toxicol (2005).
29. K. Srinivasan, B. Viswanad, L. Asrat, C.L. Kaul and P. Ramarao, Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening, Pharmacol Res 52(4) (2005), 313-320.
30. L.M. Karabatas, C. Pastorale, L.F. de Bruno, F. Maschi, O.H. Pivetta, Y.B. Lombardo et al., Early manifestations in multiple-low-dose streptozotocin-induced diabetes in mice, Pancreas 30(4) (2005), 318-324.
31. J.G. Mabley, G.J. Southan, A.L. Salzman and C. Szabo, The combined inducible nitric oxide synthase inhibitor and free radical scavenger guanidinoethyldisulfide prevents multiple low-dose streptozotocin-induced diabetes in vivo and interleukin-1 beta-induced suppression of islet insulin secretion in vitro, Pancreas 28(2) (2004), E39-44.
32. S.M. de la Monte, T. Luong, T.R. Neely, D. Robinson and J.R. Wands, Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease, Lab Invest 80(8) (2000), 1323-1335.
33. J.E. Yeon, S. Califano, J. Xu, J.R. Wands and S.M. De La Monte, Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver, Hepatology 38(3) (2003), 703-714.
34. F. Ausubel, R. Brent, R. Kingston, D. Moore, J. Seidman, J. Smnith et al., Current Protocols in Molecular Biology (2000).
35. M.D. Mythili, R. Vyas, G. Akila and S. Gunasekaran, Effect of streptozotocin on the ultrastructure of rat pancreatic islets, Microsc Res Tech 63(5) (2004), 274-281.
36. C. Sotelo and M. Wassef, Cerebellar development: afferent organization and Purkinje cell heterogeneity, Philos Trans R Soc Lond B Biol Sci 331(1261) (1991), 307-313.
37. A. Ullrich, J.R. Bell, E.Y. Chen, R. Herrera, L.M. Petruzzelli, T.J. Dull et al., Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes, Nature 313(6005) (1985), 756-761.
38. M.G. Myers, X.J. Sun and M.F. White, The IRS-1 signaling system, Trends Biochem Sci 19(7) (1994), 289-293.
39. T. O'Hare and P.F. Pilch, Intrinsic kinase activity of the insulin receptor, Int J Biochem 22(4) (1990), 315-324.
40. X.J. Sun, P. Rothenberg, C.R. Kahn, J.M. Backer, E. Araki, P.A. Wilden et al., Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein, Nature 352(6330) (1991), 73-77.
41. M.F. White, R. Maron and C.R. Kahn, Insulin rapidly stimulates tyrosine phosphorylation of a Mr-185,000 protein in intact cells, Nature 318(6042) (1985), 183-186.
42. X.J. Sun, D.L. Crimmins, M.J. Myers, M. Miralpeix and M.F. White, Pleiotropic insulin signals are engaged by multisite phosphorylation of IRS-1, Mol Cell Biol 13(12) (1993), 7418-7428.
43. D.G. Puro and E. Agardh, Insulin-mediated regulation of neuronal maturation, Science 225(4667) (1984), 1170-1172.
44. J.F. Mill, M.V. Chao and D.N. Ishii, Insulin, insulin-like growth factor II, and nerve growth factor effects on tubulin mRNA levels and neurite formation, Proc Natl Acad Sci USA 82(20) (1985), 7126-7130.
45. K. Lam, C.L. Carpenter, N.B. Ruderman, J.C. Friel and K.L. Kelly, The phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1. Stimulation by insulin and inhibition by Wortmannin, J Biol Chem 269(32) (1994), 20648-20652.
46. G. Kulik, A. Klippel and M.J. Weber, Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt, Mol Cell Biol 17(3) (1997), 1595-606.
47. H. Dudek, S.R. Datta, T.F. Franke, M.J. Birnbaum, R. Yao, G.M. Cooper et al., Regulation of neuronal survival by the serine-threonine protein kinase Akt [see comments], Science 275(5300) (1997), 661-665.
48. B.M. Burgering and P.J. Coffer. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction, Nature 376(6541) (1995), 599-602.
49. M. Delcommenne, C. Tan, V. Gray, L. Rue, J. Woodgett and S. Dedhar, Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase, Proc Natl Acad Sci USA 95(19) (1998), 11211-11216.
50. K. Iqbal, C. Alonso Adel, S. Chen, M.O. Chohan, E. El-Akkad, C.X. Gong et al., Tau pathology in Alzheimer disease and other tauopathies, Biochim Biophys Acta 1739(2-3) (2005), 198-210.
51. S. Lovestone, C.H. Reynolds, D. Latimer, D.R. Davis, B.H. Anderton, J.M. Gallo et al., Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells, Curr Biol 4(12) (1994), 1077-1086.
52. A.K. Godbolt, K.A. Josephs, T. Revesz, E.K. Warrington, P. Lantos, A. King et al., Sporadic and familial dementia with ubiquitin-positive tau-negative inclusions: clinical features of one histopathological abnormality underlying frontotemporal lobar degeneration, Arch Neurol 62(7) (2005), 1097-1101.
53. K.S. Kosik and H. Shimura, Phosphorylated tau and the neurodegenerative foldopathies, Biochim Biophys Acta 1739(2-3) (2005), 298-310.
54. F.M. de Vrij, D.F. Fischer, F.W. van Leeuwen and E.M. Hol, Protein quality control in Alzheimer's disease by the ubiquitin proteasome system, Prog Neurobiol 74(5) (2004), 249-270.
55. S.M. de la Monte, G.J. Chen, E. Rivera and J.R. Wands, Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells, Cell Mol Life Sci 60(12) (2003), 2679-2691.
56. M. Hong and V.M. Lee, Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons, J Biol Chem 272(31) (1997), 19547-19553.
57. S.M. de la Monte, Quantitation of cerebral atrophy in pre-clinical and end-stage Alzheimer's disease, Ann Neurol 25(5) (1989), 450-459.
58. E. Recio-Pinto, M.M. Rechler and D.N. Ishii, Effects of insulin, insulin-like growth factor-II, and nerve growth factor on neurite formation and survival in cultured sympathetic and sensory neurons, J Neurosci 6(5) (1986), 1211-1219.
59. S.R. D'Mello, K. Borodezt and S.P. Soltoff, Insulin-like growth factor and potassium depolarization maintain neuronal survival by distinct pathways: possible involvement of PI3-kinase in IGF-1 signaling, J Neurosci 17(5) (1997), 1548-1560.
60. A.J. D'Ercole, P. Ye, A.S. Calikoglu and G. Gutierrez-Ospina, The role of the insulin-like growth factors in the central nervous system, Mol Neurobiol 13(3) (1996), 227-255.
61. P. Eikelenboom and W.A. van Gool, Neuroinflammatory perspectives on the two faces of Alzheimer's disease, J Neural Transm 111(3) (2004), 281-294.
62. I. Blasko, M. Stampfer-Kountchev, P. Robatscher, R. Veerhuis, P. Eikelenboom and B. Grubeck-Loebenstein, How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes, Aging Cell 3(4) (2004), 169-176.
63. E.E. Tuppo and H.R. Arias, The role of inflammation in Alzheimer's disease, Int J Biochem Cell Biol 37(2) (2005), 289-305.
64. J.H. Su, G. Deng and C.W. Cotman, Bax protein expression is increased in Alzheimer's brain: correlations with DNA damage, Bcl-2 expression, and brain pathology, J Neuropathol Exp Neurol 56(1) (1997), 86-93.
65. S.M. de la Monte, Y.K. Sohn and J.R. Wands, Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease, J Neurol Sci 152(1) (1997), 73-83.
66. S. Doublier, C. Duyckaerts, D. Seurin and M. Binoux, Impaired brain development and hydrocephalus in a line of transgenic mice with liver-specific expression of human insulin-like growth factor binding protein-1, Growth Horm IGF Res 10(5) (2000), 267-274.
67. T. Nishiyama, T. Shirotani, T. Murakami, F. Shimada, M. Todaka, S. Saito et al., Expression of the gene encoding the tyrosine kinase-deficient human insulin receptor in transgenic mice, Gene 141(2) (1994), 187-192.
68. U. Smith, M. Axelsen, E. Carvalho, B. Eliasson, P.A. Jansson and C. Wesslau, Insulin signaling and action in fat cells: associations with insulin resistance and type 2 diabetes, Ann N Y Acad Sci 892 (1999), 119-126.
69. G.J. Chen, J. Xu, S.A. Lahousse, N.L. Caggiano and S.M. de la Monte, Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection, J Alzheimers Dis 5(3) (2003), 209-228.
70. L. Xie, E. Helmerhorst, K. Taddei, B. Plewright, W. Van Bronswijk and R. Martins, Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor, J Neurosci 22(10) (2002), RC221.
71. A. Hye, F. Kerr, N. Archer, C. Foy, M. Poppe, R. Brown et al., Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease, Neurosci Lett 373(1) (2005), 1-4.
72. S.E. Nikoulina, T.P. Ciaraldi, S. Mudaliar, P. Mohideen, L. Carter and R.R. Henry, Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes, Diabetes 49(2) (2000), 263-271.
73. A. Lorenzo and B.A. Yankner, Amyloid fibril toxicity in Alzheimer's disease and diabetes, Ann N Y Acad Sci 777 (1996), 89-95.
74. T. Niikura, Y. Hashimoto, H. Tajima and I. Nishimoto, Death and survival of neuronal cells exposed to Alzheimer's insults, J Neurosci Res 70(3) (2002), 380-391.
75. E. Tsukamoto, Y. Hashimoto, K. Kanekura, T. Niikura, S. Aiso and I. Nishimoto, Characterization of the toxic mechanism triggered by Alzheimer's amyloid-beta peptides via p75 neurotrophin receptor in neuronal hybrid cells, J Neurosci Res 73(5) (2003), 627-636.
76. P. Hammond, R. Rao, C. Koenigsberger and S. Brimijoin, Regional variation in expression of acetylcholinesterase mRNA in adult rat brain analyzed by in situ hybridization, Proc Natl Acad Sci USA 91(23) (1994), 10933-10937.
77. O. Strada, S. Vyas, E.C. Hirsch, M. Ruberg, A. Brice, Y. Agid et al., Decreased choline acetyltransferase mRNA expression in the nucleus basalis of Meynert in Alzheimer disease: an in situ hybridization study, Proc Natl Acad Sci USA 89(20) (1992), 9549-9553.
78. K. Yasuyama, T. Kitamoto and P.M. Salvaterra, Differential regulation of choline acetyltransferase expression in adult Drosophila melanogaster brain, J Neurobiol 30(2) (1996), 205-218.
79. A.D. Bolzan and M.S. Bianchi, Genotoxicity of streptozotocin, Mutat Res 512(2-3) (2002), 121-134.
80. T. Szkudelski, The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas, Physiol Res 50(6) (2001), 537-546.
81. M.A. Smith and G. Perry, Free radical damage, iron, and Alzheimer's disease, J Neurol Sci 134 (1995), 92-94.
82. M.A. Smith, P.L. Richey Harris, L.M. Sayre, J.S. Beckman and G. Perry, Widespread peroxynitrite-mediated damage in Alzheimer's disease, J Neurosci 17(8) (1997), 2653-2657.
83. L.M. Sayre, D.A. Zelasko, P.L. Harris, G. Perry, R.G. Salomon and M.A. Smith, 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease, J Neurochem 68(5) (1997), 2092-2097.
84. K. Hirai, G. Aliev, A. Nunomura, H. Fujioka, R.L. Russell, C.S. Atwood et al., Mitochondrial abnormalities in Alzheimer's disease, J Neurosci 21(9) (2001), 3017-3023.
85. A. Nunomura, G. Perry, G. Aliev, K. Hirai, A. Takeda, E.K. Balraj et al., Oxidative damage is the earliest event in Alzheimer disease, J Neuropathol Exp Neurol 60(8) (2001), 759-767.
86. S.M. de la Monte and K.D. Bloch, Aberrant expression of the constitutive endothelial nitric oxide synthase gene in Alzheimer disease, Mol Chem Neuropathol 30(1-2) (1997), 139-159.
87. X. Zhu, A.K. Raina, H.G. Lee, G. Casadesus, M.A. Smith and G. Perry, Oxidative stress signalling in Alzheimer's disease, Brain Res 1000(1-2) (2004), 32-39.
88. A.D. Cash, G. Perry, O. Ogawa, A.K. Raina, X. Zhu and M.A. Smith, Is Alzheimer's disease a mitochondrial disorder? Neuroscientist 8(5) (2002), 489-496.
89. S.M. de la Monte, N. Ganju, N. Feroz, T. Luong, K. Banerjee, J. Cannon et al., Oxygen free radical injury is sufficient to cause some Alzheimer-type molecular abnormalities in human CNS neuronal cells, J Alzheimers Dis 2(3-4) (2000), 261-281.
90. S.M. de la Monte, W. Garner and J.R. Wands, Neuronal thread protein gene modulation with cerebral infarction, J Cereb Blood Flow Metab 17(6) (1997), 623-635.
91. S.M. de la Monte, T.R. Neely, J. Cannon and J.R. Wands, Oxidative stress and hypoxia-like injury cause Alzheimer-type molecular abnormalities in central nervous system neurons, Cell Mol Life Sci 57(10) (2000), 1471-1481.
92. M.A. Smith, K. Hirai, K. Hsiao, M.A. Pappolla, P.L. Harris, S.L. Siedlak et al., Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress, J Neurochem 70(5) (1998), 2212-2215.
93. M.A. Pappolla, Y.J. Chyan, R.A. Omar, K. Hsiao, G. Perry, M.A. Smith et al., Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo, Am J Pathol 152(4) (1998), 871-877.
94. D. Etiene, J. Kraft, N. Ganju, T. Gomez-Isla, B. Gemelli and B.T. Hyman et al., Cerebrovascular Pathology Contributes to the Heterogeneity of Alzheimer's Disease, J Alzheimers Dis 1(2) (1998), 119-134.
95. K.A. Jellinger, Alzheimer disease and cerebrovascular pathology: an update, J Neural Transm 109(5-6) (2002), 813-836.